Genmab A/S (GNMSF)
USD 200.0
(0.96%)
USD 200.0
(0.96%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 15.92 Billion DKK | 9.09% |
| 2022 | 14.59 Billion DKK | 72.07% |
| 2021 | 8.48 Billion DKK | -16.11% |
| 2020 | 10.11 Billion DKK | 88.43% |
| 2019 | 5.36 Billion DKK | 77.38% |
| 2018 | 3.02 Billion DKK | 27.89% |
| 2017 | 2.36 Billion DKK | 30.25% |
| 2016 | 1.81 Billion DKK | 60.29% |
| 2015 | 1.13 Billion DKK | 33.24% |
| 2014 | 850.38 Million DKK | 28.15% |
| 2013 | 663.57 Million DKK | 36.92% |
| 2012 | 484.63 Million DKK | 366.91% |
| 2011 | -181.57 Million DKK | -41640.46% |
| 2010 | -435 Thousand DKK | -100.07% |
| 2009 | 586.07 Million DKK | -15.83% |
| 2008 | 696.3 Million DKK | 31.49% |
| 2007 | 529.53 Million DKK | 290.67% |
| 2006 | 135.54 Million DKK | 37.6% |
| 2005 | 98.5 Million DKK | 2301.98% |
| 2004 | 4.1 Million DKK | -94.0% |
| 2003 | 68.32 Million DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 5.21 Billion DKK | 31.68% |
| 2024 Q1 | 3.95 Billion DKK | -13.05% |
| 2023 Q3 | 4.64 Billion DKK | 11.18% |
| 2023 Q1 | 2.85 Billion DKK | -45.4% |
| 2023 FY | 15.92 Billion DKK | 9.09% |
| 2023 Q2 | 4.17 Billion DKK | 46.36% |
| 2023 Q4 | 4.55 Billion DKK | -1.98% |
| 2022 FY | 14.59 Billion DKK | 72.07% |
| 2022 Q2 | 3.16 Billion DKK | 49.22% |
| 2022 Q1 | 2.11 Billion DKK | -19.09% |
| 2022 Q3 | 4.08 Billion DKK | 29.25% |
| 2022 Q4 | 5.22 Billion DKK | 27.89% |
| 2021 FY | 8.48 Billion DKK | -16.11% |
| 2021 Q4 | 2.61 Billion DKK | 13.38% |
| 2021 Q3 | 2.31 Billion DKK | 17.14% |
| 2021 Q2 | 1.97 Billion DKK | 24.73% |
| 2021 Q1 | 1.58 Billion DKK | -22.65% |
| 2020 Q3 | 1.72 Billion DKK | -68.37% |
| 2020 FY | 10.11 Billion DKK | 88.43% |
| 2020 Q4 | 2.04 Billion DKK | 18.56% |
| 2020 Q2 | 5.45 Billion DKK | 511.1% |
| 2020 Q1 | 892 Million DKK | -69.88% |
| 2019 Q3 | 1.03 Billion DKK | 34.36% |
| 2019 Q2 | 773.91 Million DKK | 30.95% |
| 2019 Q1 | 591 Million DKK | -52.18% |
| 2019 Q4 | 2.96 Billion DKK | 184.78% |
| 2019 FY | 5.36 Billion DKK | 77.38% |
| 2018 Q2 | 509.67 Million DKK | -25.16% |
| 2018 Q1 | 681.01 Million DKK | -33.09% |
| 2018 FY | 3.02 Billion DKK | 27.89% |
| 2018 Q4 | 1.23 Billion DKK | 106.46% |
| 2018 Q3 | 598.59 Million DKK | 17.45% |
| 2017 FY | 2.36 Billion DKK | 30.25% |
| 2017 Q4 | 1.01 Billion DKK | 214.69% |
| 2017 Q2 | 773.34 Million DKK | 208.38% |
| 2017 Q3 | 323.44 Million DKK | -58.18% |
| 2017 Q1 | 250.77 Million DKK | -72.96% |
| 2016 Q3 | 364.66 Million DKK | 3.06% |
| 2016 FY | 1.81 Billion DKK | 60.29% |
| 2016 Q4 | 927.46 Million DKK | 154.33% |
| 2016 Q1 | 170.17 Million DKK | -70.39% |
| 2016 Q2 | 353.82 Million DKK | 107.92% |
| 2015 Q1 | 106.77 Million DKK | -50.52% |
| 2015 Q3 | 277.76 Million DKK | 59.78% |
| 2015 Q2 | 173.84 Million DKK | 62.81% |
| 2015 Q4 | 574.65 Million DKK | 106.89% |
| 2015 FY | 1.13 Billion DKK | 33.24% |
| 2014 Q3 | 271.52 Million DKK | 134.09% |
| 2014 FY | 850.38 Million DKK | 28.15% |
| 2014 Q4 | 215.8 Million DKK | -20.52% |
| 2014 Q2 | 115.98 Million DKK | -53.06% |
| 2014 Q1 | 247.07 Million DKK | 14.36% |
| 2013 Q3 | 149.66 Million DKK | 8.38% |
| 2013 FY | 663.57 Million DKK | 36.92% |
| 2013 Q2 | 138.09 Million DKK | -13.57% |
| 2013 Q1 | 159.77 Million DKK | -2.04% |
| 2013 Q4 | 216.04 Million DKK | 44.35% |
| 2012 Q1 | -29.04 Million DKK | 40.89% |
| 2012 Q4 | 163.1 Million DKK | 40.76% |
| 2012 FY | 484.63 Million DKK | 366.91% |
| 2012 Q2 | -21.15 Million DKK | 27.17% |
| 2012 Q3 | 115.87 Million DKK | 647.83% |
| 2011 Q1 | -44.35 Million DKK | 22.46% |
| 2011 Q3 | -40.41 Million DKK | 15.21% |
| 2011 Q2 | -47.66 Million DKK | -7.47% |
| 2011 FY | -181.57 Million DKK | -41640.46% |
| 2011 Q4 | -49.13 Million DKK | -21.55% |
| 2010 Q4 | -57.2 Million DKK | -129.53% |
| 2010 Q2 | -23.26 Million DKK | 79.54% |
| 2010 Q1 | -113.68 Million DKK | -158.93% |
| 2010 FY | -435 Thousand DKK | -100.07% |
| 2010 Q3 | 193.71 Million DKK | 932.7% |
| 2009 Q1 | 249.98 Million DKK | 0.0% |
| 2009 FY | 586.07 Million DKK | -15.83% |
| 2009 Q3 | -107.9 Million DKK | -245.48% |
| 2009 Q4 | 192.89 Million DKK | 278.77% |
| 2009 Q2 | 74.17 Million DKK | -70.33% |
| 2008 FY | 696.3 Million DKK | 31.49% |
| 2007 FY | 529.53 Million DKK | 290.67% |
| 2006 FY | 135.54 Million DKK | 37.6% |
| 2005 FY | 98.5 Million DKK | 2301.98% |
| 2004 FY | 4.1 Million DKK | -94.0% |
| 2003 FY | 68.32 Million DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | -135907.176% |
| BioStem Technologies, Inc. | 15.42 Million USD | -103116.583% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -13266.908% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 61814.086% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -9017231.219% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -11331572.598% |
| Arch Therapeutics, Inc. | -2439.00 USD | 652767627.675% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 4983089.418% |
| Qrons Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 12813678.965% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 32990837.479% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | -110.567% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -165553.938% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -106047.076% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -513249416.441% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -162458.709% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -24222453.554% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 46620890.63% |
| Mesoblast Limited | -35.16 Million USD | 45371.269% |
| Marizyme, Inc. | 457.7 Thousand USD | -3478364.154% |
| Genus plc | 178.7 Million USD | -8809.345% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -7133.399% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -25585668.007% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -3881508.621% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 144736463.636% |
| ContraFect Corporation | -154 Thousand USD | 10338411.688% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 31842100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -20740901.29% |
| IMV Inc. | -962.29 Thousand USD | 1654577.095% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 4108734.558% |
| MultiCell Technologies, Inc. | 49.32 USD | -32281021797.81% |
| ONE Bio Corp. | 20.12 Million USD | -79008.825% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -39440.544% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -32558182.209% |
| Q BioMed Inc. | -8988.00 USD | 177136281.575% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -56247.549% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 103222351.037% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -35792.211% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 1394755.79% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -22744185.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 321506562.036% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 16326818.966% |
| GB Sciences, Inc. | -624.00 USD | 2551442407.692% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 18506865.239% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 7654327023.077% |
| Enzolytics Inc. | 30.7 Thousand USD | -51846324.385% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -3300047.378% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | -1336.29% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 3094500.498% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2578684.031% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | -3787.409% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 179776522.764% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 18987804.087% |
| Kadimastem Ltd | -630.13 Thousand USD | 2526689.414% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -1611368.237% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 134524814.829% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -9017231.219% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -1173026.192% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 54900100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -3537561.957% |
| SYBLEU INC | 11.69 Thousand USD | -136123361.012% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -345407.813% |
| Bioxytran, Inc. | -8285.00 USD | 192166666.083% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 4268464.611% |
| Neutra Corp. | 14.33 Thousand USD | -111063729.787% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 19415953.659% |
| PureTech Health plc | -1.6 Million USD | 993300.25% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 1590234.594% |
| IXICO plc | 3.27 Million USD | -486780.734% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 2294192.219% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 889044.724% |
| CSL Limited | 7.7 Billion USD | -106.632% |
| Cellectis S.A. | 18 Thousand USD | -88449900.0% |